Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 5370.

https://doi.org/10.1182/blood-2025-5370

Published: 2025

Journal Articles

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

Amir Ali, Pallawi Torka, Yucai Wang, Tara Graff, Erin Mulvey, Yumeng Zhang, Monika Jun, Abualbishr Alshreef, Alex Mutebi, Anthony Wang, David Tybor, Lynn Huynh, Angela Lax, Tychell Branchcomb, Mei Sheng Duh, Javier Munoz, Muhamad Alhaj Moustafa, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 8075.

https://doi.org/10.1182/blood-2025-8075

Published: 2025

Journal Articles

Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL

Tara Graff, Savreet Bains Chawla, Monika Jun, Nicole Heaps, Abualbishr Alshreef, David Tybor, Nadine Zawadzki, Kathryn Spurrier, Jason Shafrin

Blood (2025) 146 (Supplement 1): 7942.

https://doi.org/10.1182/blood-2025-7942

Published: 2025

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7760.

https://doi.org/10.1182/blood-2024-203876

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7757.

https://doi.org/10.1182/blood-2024-203540

Published: 2024

Journal Articles

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Christopher P Fox, Peter A. Riedell, Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony W Wang, Abualbishr Alshreef

Blood (2024) 144 (Supplement 1): 7614.

https://doi.org/10.1182/blood-2024-207898

Published: 2024

Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 2349.

https://doi.org/10.1182/blood-2024-203994

Published: 2024

Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont

Blood (2023) 142 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2023-180047

Published: 2023

Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov

Blood (2022) 140 (Supplement 1): 10934–10935.

https://doi.org/10.1182/blood-2022-158028

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only